Kinases are an intracellular communications network that cells use to communicate stimuli from the cell membrane to the nucleus so it can react to its environment,” explains Jeffry Vaught, Ph.D. One of the functions of kinases in the cell is to communicate when it is time for apoptosis: a mechanism that enables organisms to eliminate cells that are no longer needed or are seriously damaged. In a neurological disease like Parkinson’s disease, the apoptosis of neurons is an unwanted event. Kinases inhibitors work by interfering with the function of apoptosis. Another term for this is kinases apopotis inhibitors.
PRECEPT - Cephalon/Lundbeck phase II/III clinical trial of CEP-1347.
CEP-1347 is a small molecule inhibitor of the mixed-lineage kinase (MLK) family of kinases. In cell cultures and animal models, CEP-1347 has shown the ability to slow cell death. CEP-1347 showed potential to both retard Parkinson’s disease progression and also reverse the severity of symptoms by improving the function of surviving neurons.
In May 2005 Cephalon halted the CEP-1347 trial after interim results were reviewed. They concluded that the data were "unlikely to provide evidence of significant effect."
CEP-1347 was a multi-year, 800-patient Phase II/III clinical trial in collaboration with H. Lundbeck A/S. The trial ended on May 11, 2005.
 Cephalon, Interview with Jeffry Vaught, Ph.D., Senior Vice President, and President of Research and Development
 Cephalon, March 10, 2005
 Abstract: Annual Review of Pharmacology and Toxicology; Vol. 44: 451-474 (Volume publication date February 2004), (doi:10.1146/annurev.pharmtox.44.101802.121840) First posted online on September 8, 2003
 Cephalon and H. Lundbeck Announce Discontinuation of CEP-1347 Clinical Trial in Parkinson's Disease, 5/11/05
 Cephalon, retrieved date: March 10, 2005